Physician profile
Robert G Smith
NPI 1477611960
$2,038.98
in general payments reported to CMS, 2019-2025
25 companies · $493 in 2025
The $493 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $139 · 2021: $327 · 2022: $315 · 2023: $168 · 2024: $377 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,003 · Education: $35.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,002.80 |
| Education | $35.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $313.20 | 2021-2025 | Qulipta, Botox |
| Novartis Pharmaceuticals Corporation | $224.46 | 2021-2025 | |
| Avanir Pharmaceuticals, INC. | $178.53 | 2019-2022 | |
| Pfizer INC. | $145.91 | 2024-2025 | |
| Genzyme Corporation | $138.46 | 2025 | |
| Ucb, INC. | $134.05 | 2024 | |
| Allergan, INC. | $130.56 | 2019-2021 | |
| Eisai INC. | $125.00 | 2024 | |
| Sunovion Pharmaceuticals INC. | $87.37 | 2019-2020 | |
| Biogen, INC. | $73.66 | 2019-2025 | Vumerity, Spinraza |
| Alexion Pharmaceuticals, INC. | $70.07 | 2021-2025 | Ultomiris |
| Csl Behring | $60.47 | 2024-2025 | Hizentra |
| Argenx US, INC. | $42.97 | 2022-2024 | Vyvgart Hytrulo |
| Horizon Therapeutics Plc | $42.27 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $39.48 | 2020-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Strongbridge US INC. | $33.55 | 2019 | |
| Ge Healthcare | $31.73 | 2023 | |
| Emd Serono, INC. | $30.96 | 2019 | |
| Amgen INC. | $29.92 | 2020 | |
| Xeris Pharmaceuticals, INC. | $20.24 | 2025 | Keveyis |
| Cadwell Industries, INC | $19.36 | 2022 | |
| Tanabe Pharma America, INC. | $18.18 | 2025 | Radicava |
| Grt US Holding, INC. | $17.08 | 2020 | |
| Shire North American Group INC | $16.51 | 2019 | |
| Averitas Pharma INC. | $14.99 | 2025 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.